scholarly journals Assessment of the efficacy of platelet-rich plasma injections in the management of severe dry eye

2021 ◽  
Vol 114 (3) ◽  
pp. 63
Author(s):  
KareemB Elessawy ◽  
AhmadB Araissi ◽  
HaythamE Nasr ◽  
SamehH Abdelbaky
Keyword(s):  
Dry Eye ◽  
Platelet Rich Plasma

scholarly journals Comparison of treatment efficacy between 100% platelet-rich plasma and 100% serum eye drops in moderate-to-severe dry eye disease: a randomised controlled trial protocol

BMJ Open ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. e048479
Author(s):  
Passara Jongkhajornpong ◽  
Pawin Numthavaj ◽  
Thunyarat Anothaisintawee ◽  
Kaevalin Lekhanont ◽  
Gareth McKay ◽  
...  
Keyword(s):  
Dry Eye ◽  
Ocular Surface ◽  
Platelet Rich Plasma ◽  
Controlled Trial ◽  
Dry Eye Disease ◽  
Autologous Serum ◽  
Eye Disease ◽  
Eye Drops ◽  
Department Of Ophthalmology ◽  
Autologous Platelet

IntroductionDry eye disease (DED) is a common eye problem. Although the disease is not fatal, it substantially reduces quality of life and creates a high economic burden, especially in patients with moderate-to-severe DED. Several biological tear substitutes (eg, autologous serum (AS), autologous platelet-rich plasma (APRP) and autologous platelet lysate) could effectively improve dry eyes. However, evidence on their comparative efficacy is controversial. This study aims to compare the efficacy of 100% APRP with 100% AS eye drops in patients with moderate-to-severe DED.Methods and analysisThe study is a single-centre, double-blinded randomised, parallel, non-inferiority trial. One hundred and thirty patients with moderate-to-severe DED, aged 18–70 years will be recruited from outpatient clinic, Department of Ophthalmology, Ramathibodi Hospital, Bangkok from February 2021 to January 2023. Patients will be randomised to receive either 100% APRP or 100% AS eye drops (1:1 ratio) for 4 weeks. The primary outcomes are ocular surface disease index (OSDI) and ocular surface staining (OSS) evaluated using the Oxford scale. Secondary outcomes are fluorescein break-up time, Schirmer’s I test, meibomian gland parameters and adverse events. Other measured outcomes include best-corrected visual acuity, intraocular pressure and compliance.Ethics and disseminationThe study protocol and any supplements used in conducting this trial have been approved by the Ethics Committee of Faculty of Medicine, Ramathibodi Hospital, Mahidol University (MURA2020/1930). Informed consent will be obtained from all patients before study entry. Results will be presented in peer-reviewed journals and international conferences.Trial registration numberNCT04683796.

scholarly journals Efficacy and safety of treatment of hyposecretory dry eye with platelet‐rich plasma

2018 ◽  
Vol 97 (2) ◽  
Author(s):  
Víctor García‐Conca ◽  
Marta Abad‐Collado ◽  
Jose R Hueso‐Abancens ◽  
Encarna Mengual‐Verdú ◽  
David P Piñero ◽  
...  
Keyword(s):  
Dry Eye ◽  
Platelet Rich Plasma ◽  
Efficacy And Safety

scholarly journals Randomised, prospective clinical trial of platelet-rich plasma injection in the management of severe dry eye

2018 ◽  
Vol 103 (5) ◽  
pp. 648-653 ◽  
Author(s):  
Marcel Y Avila ◽  
Angela M Igua ◽  
Amparo M Mora
Keyword(s):  
Hyaluronic Acid ◽  
Outcome Measures ◽  
Dry Eye ◽  
Primary Outcome ◽  
Platelet Rich Plasma ◽  
Intervention Group ◽  
Treatment Compliance ◽  
Secondary Outcome ◽  
Control Group ◽  
Corneal Staining

BackgroundTo evaluate the effectiveness of platelet-rich plasma (PRP) injections in the treatment of severe dry eye.MethodsThis prospective, intervention study included patients with severe dry eye who had been diagnosed with Sjogren syndrome. Patients were divided into two groups. The intervention group received PRP (n=15) injections on days 0, 30, 60 and 90, as well as hyaluronic acid five times per day. The comparison group received hyaluronic acid (n=15) five times per day. Subjects were measured at baseline and at 30, 60 and 90 days. The primary outcome measures were changes in corneal staining according to the Oxford classification, results of the Schirmer test and tear break-up time (TBUT). The secondary outcome measures were changes in the Ocular Surface Disease Index (OSDI) and treatment compliance.ResultsAll subjects completed the study. The intervention group showed improvements in all primary outcome measures when compared with the control group, including a reduction in corneal staining (p<0.001), increase in the mean Schirmer value from 5.6±0.7 to 9.0±1.1 mm, and an increase in TBUT from 4.0±0.4 to 6.4±0.4 s at day 90. An improvement in subjective OSDI values was also found.ConclusionPRP injection is safe and effective in improving tear parameters as well as subjective parameters, and was found to be superior to hyaluronic acid alone in the management of patients with severe dry eye. This represent a novel alternative treatment for severe dry eye.Trial registration numberNCT02257957.

scholarly journals Treatment of Dry Eye Disease with Autologous Platelet-Rich Plasma: A Prospective, Interventional, Non-Randomized Study

2017 ◽  
Vol 6 (2) ◽  
pp. 285-293 ◽  
Author(s):  
Jorge L. Alio ◽  
Alejandra E. Rodriguez ◽  
Renan Ferreira-Oliveira ◽  
Dominika Wróbel-Dudzińska ◽  
Ahmed A. Abdelghany
Keyword(s):  
Dry Eye ◽  
Platelet Rich Plasma ◽  
Randomized Study ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Autologous Platelet Rich Plasma ◽  
Autologous Platelet

scholarly journals Bilateral Congenital Ectropion Uveae, Anterior Segment Dysgenesis and Aniridia with Microspherophakic Congenital Cataracts and RubeosisIridis

2018 ◽  
Vol 2 (1) ◽  
Keyword(s):  
Dry Eye ◽  
Platelet Rich Plasma ◽  
Anterior Segment ◽  
Tear Film ◽  
Hair Follicles ◽  
High Rate ◽  
Adequate Treatment ◽  
Anterior Segment Dysgenesis ◽  
Possible Cause ◽  
Demodex Infestation

In recent times, multiple eye diseases have been seen associated with an increase in the rate of Demodex infestation as a possible cause, but in the particular case of dry eye syndrome in patients treated with platelet-rich plasma, this increase in mite may be relevant to guide a more adequate treatment focusing on the elimination of the mite in conjunction with the recovery of the ocular ecology. The demodex mite is a commensal parasite that lives in hair follicles, sebaceous glands and meibomian, which in a high rate of infestation can generate alterations in the ocular area. Performing an adequate diagnosis for the detection of the mite and treatment for its eradication can be effective for the recovery of the normal physiology of the tear film that constitutes a cause of dry eye.

Symptomatic Dry Eye Treatment with Autologous Platelet-Rich Plasma

2007 ◽  
Vol 39 (3) ◽  
pp. 124-129 ◽  
Author(s):  
Jorge L. Alio ◽  
José R. Colecha ◽  
Silvia Pastor ◽  
Alejandra Rodriguez ◽  
Alberto Artola
Keyword(s):  
Dry Eye ◽  
Platelet Rich Plasma ◽  
Autologous Platelet Rich Plasma ◽  
Autologous Platelet
Sign in / Sign up

Export Citation Format

Share Document